Dr. Martens (LON:DOCS) Insider Giles Wilson Buys 179 Shares

Dr. Martens plc (LON:DOCS) insider Giles Wilson acquired 179 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were bought at an average cost of GBX 84 per share, with a total value of £150.36.

Giles Wilson also recently made the following trade(s):

• On Thursday, June 25th, Giles Wilson acquired 68,313 shares of Dr. Martens stock. The shares were purchased at an average cost of GBX 72 per share, for a total transaction of £49,185.36.
• On Thursday, June 11th, Giles Wilson bought 202 shares of Dr. Martens stock. The stock was purchased at an average cost of GBX 74 per share, with a total value of £149.48.

Dr. Martens Price Performance

Shares of DOCS stock traded up GBX 0.60 during mid-day trading on Thursday, reaching GBX 88.80. The company’s stock had a trading volume of 18,918,002 shares, compared to its average volume of 7,381,275. The company has a debt-to-equity ratio of 108.85, a quick ratio of 1.13 and a current ratio of 2.61. The firm’s 50-day moving average is GBX 74.52 and its two-hundred day moving average is GBX 69.18. Dr. Martens plc has a 1-year low of GBX 59.15 and a 1-year high of GBX 100.87. The company has a market cap of £849.92 million, a P/E ratio of 37.00, a PEG ratio of 6.40 and a beta of 0.26.

Dr. Martens (LON:DOCS) last posted its earnings results on Tuesday, May 19th. The company reported GBX 4.20 earnings per share for the quarter. The business had revenue of £764.90 million for the quarter. Dr. Martens had a net margin of 3.11% and a return on equity of 6.89%. On average, research analysts predict that Dr. Martens plc will post 2.5809394 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Berenberg Bank decreased their price target on Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Royal Bank Of Canada reiterated a “sector perform” rating and set a GBX 100 target price on shares of Dr. Martens in a research report on Tuesday, June 2nd. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Dr. Martens has an average rating of “Moderate Buy” and an average price target of GBX 105.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.